How does fosdenopterin hydrobromide fix molybdenum cofactor deficiency?
Fosdenopterin hydrobromide provides cyclic pyranopterin monophosphate (cPMP), a missing enzyme cofactor that the body cannot make due to MOCS1 gene mutations. The body converts cPMP into molybdenum cofactor, which activates sulfite oxidase—an enzyme that breaks down neurotoxic sulfites that otherwise accumulate in the brain and spinal cord, causing seizures and developmental damage [1].
In molybdenum cofactor deficiency Type A, mutations in the MOCS1 gene block the body's ability to manufacture cPMP, the building block for molybdenum cofactor. Without this cofactor, sulfite oxidase cannot function, and toxic sulfites pile up in the nervous system. Fosdenopterin hydrobromide bypasses this broken factory by delivering cPMP directly into the bloodstream via IV infusion [1].
Once infused, fosdenopterin hydrobromide travels to cells throughout the body and is converted into molybdenum cofactor. This cofactor then activates sulfite oxidase, which rapidly breaks down accumulated sulfites into harmless sulfate. Within weeks, seizure frequency drops 50–80%, and developmental milestones—speech, motor skills, learning—resume as the neurotoxic burden lifts [1].
The medication works best when started early (before age 2–3) and requires lifelong IV infusions every 4 weeks. Kidney function (eGFR ≥60) must be monitored because declining renal clearance slows sulfite elimination, requiring longer dosing intervals. Cost is high ($324 per dose retail), but copay assistance programs reduce out-of-pocket to $0–$50 monthly [1][2].
Ask your metabolic specialist: 'Is my child's eGFR ≥60, and are we tracking urine sulfite levels monthly to confirm the medication is working?' Early seizure control and normal development depend on consistent dosing and kidney monitoring.